Kang AS - Search Results

1

Immunogenicity of biologics used in the treatment of asthma.

Neunie OAM, Rabbani W, Baker D, Chambers ES, Pfeffer PE, Kang AS. Neunie OAM, et al. Among authors: kang as. Hum Antibodies. 2024;32(3):121-128. doi: 10.3233/HAB-240002. Hum Antibodies. 2024. PMID: 38905039 Review.

2

Immunogenicity of biologics used in the treatment of moderate to severe psoriasis.

Patel V, Efimov A, Baker D, Kang AS. Patel V, et al. Among authors: kang as. Hum Antibodies. 2021;29(3):171-178. doi: 10.3233/HAB-210447. Hum Antibodies. 2021. PMID: 34151782 Review.

3

Immunogenicity of biologics used in the treatment of inflammatory bowel disease.

Bqain M, Efimov A, Baker D, Kang AS. Bqain M, et al. Among authors: kang as. Hum Antibodies. 2021;29(4):225-235. doi: 10.3233/HAB-210449. Hum Antibodies. 2021. PMID: 34151784 Review.

4

Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis.

Baker D, Asardag AN, Quinn OA, Efimov A, Kang AS. Baker D, et al. Among authors: kang as. Hum Antibodies. 2021;29(4):255-262. doi: 10.3233/HAB-210453. Hum Antibodies. 2021. PMID: 34397407

5

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. Baker D, et al. Among authors: kang as. Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12. Mult Scler Relat Disord. 2020. PMID: 32464584 Free PMC article. Review.

6

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. Baker D, et al. Among authors: kang as. Clin Exp Immunol. 2022 May 12;207(3):263-271. doi: 10.1093/cei/uxab015. Clin Exp Immunol. 2022. PMID: 35553629 Free PMC article.

7

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis.

Baker D, Kang AS, Giovannoni G, Schmierer K. Baker D, et al. Among authors: kang as. Mult Scler Relat Disord. 2024 Feb;82:105400. doi: 10.1016/j.msard.2023.105400. Epub 2023 Dec 22. Mult Scler Relat Disord. 2024. PMID: 38181696 Free article. Review.

8

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.

Baker D, Ali L, Saxena G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S, Munger KC, Samkoff L, Goodman A, Kang AS. Baker D, et al. Among authors: kang as. Front Immunol. 2020 Feb 14;11:124. doi: 10.3389/fimmu.2020.00124. eCollection 2020. Front Immunol. 2020. PMID: 32117274 Free PMC article.

9

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. Baker D, et al. Among authors: kang as. Mult Scler Relat Disord. 2022 Jan;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 4. Mult Scler Relat Disord. 2022. PMID: 34902760 Free PMC article.

10

Alemtuzumab depletion failure can occur in multiple sclerosis.

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K. Dubuisson N, et al. Among authors: kang as. Immunology. 2018 Jun;154(2):253-260. doi: 10.1111/imm.12879. Epub 2018 Jan 4. Immunology. 2018. PMID: 29247512 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters